Catalyst Biosciences Inc (NASDAQ: GYRE) stock closed at $8.57 on 3/18/25 after a major decline of -30.2%. Moreover, trading volume in this decline was exceptionally high at 812% of normal. The stock has declined -17.0% during the last week and has been weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Catalyst Biosciences is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment